Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) and Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, risk, dividends and profitability.
Profitability
This table compares Praxis Precision Medicines and Avalo Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Praxis Precision Medicines | N/A | -34.15% | -32.42% |
| Avalo Therapeutics | N/A | -58.03% | -48.22% |
Earnings & Valuation
This table compares Praxis Precision Medicines and Avalo Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Praxis Precision Medicines | $8.55 million | 810.63 | -$303.27 million | ($12.93) | -19.20 |
| Avalo Therapeutics | $59,000.00 | 10,916.89 | -$78.26 million | ($4.37) | -2.75 |
Avalo Therapeutics has lower revenue, but higher earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by insiders. Comparatively, 4.5% of Avalo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings for Praxis Precision Medicines and Avalo Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Praxis Precision Medicines | 2 | 0 | 16 | 3 | 2.95 |
| Avalo Therapeutics | 1 | 0 | 12 | 0 | 2.85 |
Praxis Precision Medicines presently has a consensus price target of $610.95, indicating a potential upside of 146.11%. Avalo Therapeutics has a consensus price target of $45.10, indicating a potential upside of 275.52%. Given Avalo Therapeutics’ higher probable upside, analysts clearly believe Avalo Therapeutics is more favorable than Praxis Precision Medicines.
Volatility & Risk
Praxis Precision Medicines has a beta of 2.79, indicating that its stock price is 179% more volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.
About Praxis Precision Medicines
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
About Avalo Therapeutics
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
